参考文献/References:
[1]Schutte AE,Jafar TH,Poulter NR,et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension[J]. Cardiovasc Res,2023,119(2):381-409.
[2]Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension[J]. J Hypertens,2023,41(12):1874-2071.
[3]Fatani N,Dixon DL,Tassell BWV,et al. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension[J]. J Am Coll Cardiol,2021,77(10):1290-1299.
[4]Kario K,Tomitani N,Okawara Y,et al. Home systolic blood pressure time in therapeutic range and cardiovascular risk: the practitioner-based nationwide J-HOP study extended[J]. Hypertens Res,2023,47(1):112-119.
[5]Sideris K,Andrikou L,Thomopoulos C,et al. Blood pressure control measures and cardiovascular outcomes: a prospective hypertensive cohort[J]. Blood Press,2022,31(1):228-235.
[6]Kakaletsis N,Ntaios G,Milionis H,et al. Time of blood pressure in target range in acute ischemic stroke[J]. J Hypertens,2022,41(2):303-309.
[7]Doumas M,Tsioufis C,Fletcher R,et al. Time in therapeutic range,as a determinant of all‐cause mortality in patients with hypertension[J]. J Am Heart Assoc,2017,6(11):e007131.
[8]Park CH,Kim HW,Joo YS,et al. Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression[J]. Kidney Int,2024,105(4):835-843.
[9]Huang X,Deng S,Xie W,et al. Time in target range of systolic blood pressure and cognitive outcomes in patients with hypertension[J]. J Am Geriatr Soc,2024,72(2):423-432.
[10]Wang AJ,Jiang C,Li S,et al. Systolic blood pressure time in target range and incident atrial fibrillation in patients with hypertension: insights from the SPRINT trial[J]. Hypertension,2023,80(11):2306-2314.
[11]Cheng Y,Wang D,Yang Y,et al. Diastolic and systolic blood pressure time in target range as a cardiovascular risk marker in patients with type 2 diabetes: a post hoc analysis of ACCORD BP trial[J]. Diabetes Res Clin Pract,2023,203:110831.
[12]李勇,孙明,程家元. 射血分数保留的心力衰竭患者收缩压目标范围内时间和心血管结局的相关性分析[J]. 中国循证心血管医学杂志,2023,15(5):592-595,600.
[13]Fu GG,Zhou ZM,Jian BH,et al. Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy[J]. Am Heart J,2023,258:177-185.
[14]王艺璇. 中国高血压患者血压管理与达标时间对心血管预后影响的研究[D]. 北京：北京协和医学院,2023.
[15]Lin ZQ,Xiao ZW,Chen W,et al. Association of long-term time in target range for systolic blood pressure with cardiovascular risk in the elderly: a Chinese veteran cohort study[J]. Eur J Prev Cardiol,2023,30(10):969-977.
[16]Buckley LF,Baker WL,van Tassell BW,et al. Systolic blood pressure time in target range and major adverse kidney and cardiovascular events[J]. Hypertension,2023,80(2):305-313.
[17]Mahfoud F,Mancia G,Schmieder RE,et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range[J]. J Am Coll Cardiol,2022,80(20):1871-1880.
[18]陈歆,王继光,李燕,等. 高血压患者高质量血压管理中国专家建议[J]. 中华高血压杂志(中英文),2024,32(2):104-111.
[19]Sheikh AB,Sobotka PA,Garg I,et al. Blood pressure variability in clinical practice: past,present and the future[J]. J Am Heart Assoc,2023,12(9):e029297.
[20]Chung SC,Rodriguez MP,Duyx B,et al. Time spent at blood pressure target and the risk of death and cardiovascular diseases[J]. Plos One,2018,13(9):e0202359.
[21]Wright Jr JT,Williamson JD,Whelton PK,et al. A randomized trial of intensive versus standard blood-pressure control[J]. N Engl J Med,2015,373(22):2103-2116.
[22]B?hm M,Anker S,Mahfoud F,et al. Empagliflozin,irrespective of blood pressure,improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial[J]. Eur Heart J,2023,44(5):396-407.
[23]Maeda D,Dotare T,Matsue Y,et al. Blood pressure in heart failure management and prevention[J]. Hypertens Res,2023,46(4):817-833.
[24]Chen K,Li C,Cornelius V,et al. Prognostic value of time in blood pressure target range among patients with heart failure[J]. JACC Heart Fail,2022,10(6):369-379.
[25]González A,Ravassa S,López B,et al. Myocardial remodeling in hypertension[J]. Hypertension,2018,72(3):549-558.
[26]Yildiz M,Oktay AA,Stewart MH,et al. Left ventricular hypertrophy and hypertension[J]. Prog Cardiovasc Dis,2020,63(1):10-21.
[27]Schimmel K,Ichimura K,Reddy S,et al. Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target[J]. Front Cardiovasc Med,2022,9:886553.
[28]Mimouni M,Lajoix AD,Desmetz C. Experimental models to study endothelial to mesenchymal transition in myocardial fibrosis and cardiovascular diseases[J]. Int J Mol Sci,2023,25(1):382.
[29]Aune D,Saleh YM,Kobeissi E,et al. Blood pressure,hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies[J]. Eur J Epidemiol,2023,38(2):145-178.
[30]Chen Y,Zhang W,Sheng CS,et al. A prospective study on the association between atrial fibrillation and blood pressure in an elderly Chinese population[J]. Int J Cardiol,2023,372:113-119.
[31]Zhu X,Xiao X,Wang S,et al. Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement[J]. Front Cardiovasc Med,2022,9:925571.
[32]Kim M,Cho MS,Nam GB,et al. Controlled level and variability of systolic blood pressure on the risk of thromboembolic events in atrial fibrillation and hypertension[J]. Am J Cardiol,2022,180:37-43.
[33]Bizhanov KA,Аbzaliyev KB,Baimbetov AK,et al. Atrial fibrillation: Epidemiology,pathophysiology,and clinical complications (literature review)[J]. J Cardiovasc Electrophysiol,2023,34(1):153-165.
[34]Marazzato J,Blasi F,Golino M,et al. Hypertension and arrhythmias: a clinical overview of the pathophysiology-driven management of cardiac arrhythmias in hypertensive patients[J]. J Cardiovasc Dev Dis,2022,9(4):110.
[35]Gumprecht J,Domek M,Lip GYH,et al. Invited review: hypertension and atrial fibrillation: epidemiology,pathophysiology,and implications for management[J]. J Hum Hypertens,2019,33(12):824-836.
[36]Sagris M,Vardas EP,Theofilis P,et al. Atrial fibrillation: pathogenesis ,predisposing factors,and genetics[J]. Int J Mol Sci,2021,23(1):6.
[37]Schnabel RB,Yin X,Gona P,et al. 50 year trends in atrial fibrillation prevalence,incidence,risk factors,and mortality in the Framingham Heart Study: a cohort study[J]. Lancet,2015,386(9989):154-162.
[38]G?secki D,Kwarciany M,Kowalczyk K,et al. Blood pressure management in acute ischemic stroke[J]. Curr Hypertens Rep,2020,23(1):3.
[39]Sandset EC,Anderson CS,Bath PM,et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage[J]. Eur Stroke J,2021,6(2):Ⅱ.
[40]Webb AJS,Werring DJ. New insights into cerebrovascular pathophysiology and hypertension[J]. Stroke,2022,53(4):1054-1064.
[41]Parati G,Bilo G,Kollias A,et al. Blood pressure variability: methodological aspects,clinical relevance and practical indications for management—A European Society of Hypertension position paper ?[J]. J Hypertens,2023,41(4):527-544.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(7):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(7):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(7):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(7):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(7):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]